New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17

P. E.R. Liedke, D. Tu, L. Shepherd, Y. Chavarri-Guerra, K. I. Pritchard, V. Stearns, P. E. Goss

Research output: Contribution to journalArticle

Abstract

Purpose: New onset symptoms on adjuvant aromatase inhibitors for hormone receptor positive early breast cancer may associate with clinical outcomes. We performed this exploratory analysis of the association of new onset musculoskeletal (MSK) and vasomotor (VM) symptoms with clinical outcomes in the NCIC CTG MA.17 trial 5 years of extended adjuvant endocrine therapy with letrozole after tamoxifen. Methods: Symptoms were collected at baseline, 1, 6, and every 12 months on study. Multivariate Cox Models adjusting for age, nodal status, duration of tamoxifen and prior chemotherapy were used to compare disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) based on data collected before, and after, the unblinding between women with VM or MSK symptoms and those without. Results: Data post-unblinding showed new VM symptoms on extended letrozole significantly improved DFS and DDFS when occurring 1 month (DFS HR 0.52, 95% CI, 0.28-0.96; p = 0.04; DDFS HR 0.49, 95% CI, 0.24-0.99; p = 0.046) and 6 months (DFS HR 0.43, 95% CI, 0.24-0.78; p = 0.006; DDFS HR 0.44, 95% CI, 0.22-0.85; p = 0.02) after treatment initiation. Those with new VM symptoms at 12 months also had a significantly better DFS (HR 0.47, 95% CI 0.26, 0.84; P = 0.01) and a trend in improved DDFS. Only a trend to improved OS was found for those with VM symptoms 6 month after treatment. No significant improvement was found for those with new MSK symptoms at any time point or for any endpoint. Conclusions: New onset VM symptoms with extended letrozole may be useful in predicting treatment benefit.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalBreast
Volume27
DOIs
StatePublished - Jun 1 2016

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Extended hormonal therapy
  • Letrozole
  • Musculoskeletal symptoms
  • Vasomotor symptoms

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17'. Together they form a unique fingerprint.

  • Cite this